Senseonics shares are trading higher after the company announced that its collaboration with Mercy had the first commercial patient receive the next generation Eversense 365 CGM system, an integrated continuous glucose monitoring system for people with Type 1 and Type 2 diabetes.
Portfolio Pulse from Benzinga Newsdesk
Senseonics shares rose following the announcement of the first commercial patient receiving the next generation Eversense 365 CGM system through its collaboration with Mercy. This system is designed for continuous glucose monitoring for diabetes patients.
October 11, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Senseonics shares increased after the company announced a milestone in its collaboration with Mercy, with the first commercial use of the Eversense 365 CGM system.
The announcement of the first commercial patient receiving the Eversense 365 CGM system is a significant milestone for Senseonics, indicating progress in their product deployment and potential for increased adoption. This positive development is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100